Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $13.00

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $13.00.

Several equities analysts have issued reports on FULC shares. Wall Street Zen downgraded Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 1st. Royal Bank Of Canada raised their target price on Fulcrum Therapeutics from $5.00 to $7.00 and gave the company a “sector perform” rating in a research note on Thursday, October 30th. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Fulcrum Therapeutics in a research report on Monday, October 20th. Piper Sandler reissued an “overweight” rating and set a $16.00 price objective (up previously from $12.50) on shares of Fulcrum Therapeutics in a report on Thursday, October 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Wednesday, October 8th.

Fulcrum Therapeutics Trading Down 0.3%

Shares of Fulcrum Therapeutics stock opened at $7.63 on Wednesday. The stock has a market capitalization of $412.94 million, a price-to-earnings ratio of -6.47 and a beta of 3.02. The firm’s 50-day moving average price is $8.36 and its two-hundred day moving average price is $7.23. Fulcrum Therapeutics has a 1-year low of $2.32 and a 1-year high of $10.11.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). As a group, equities research analysts predict that Fulcrum Therapeutics will post -0.16 EPS for the current year.

Institutional Trading of Fulcrum Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Algert Global LLC lifted its holdings in Fulcrum Therapeutics by 6.0% during the 1st quarter. Algert Global LLC now owns 36,147 shares of the company’s stock worth $104,000 after buying an additional 2,030 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in shares of Fulcrum Therapeutics by 26.1% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 12,943 shares of the company’s stock valued at $89,000 after buying an additional 2,677 shares during the period. Strs Ohio raised its position in shares of Fulcrum Therapeutics by 3.7% during the third quarter. Strs Ohio now owns 77,900 shares of the company’s stock worth $717,000 after acquiring an additional 2,800 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Fulcrum Therapeutics by 2.6% during the first quarter. American Century Companies Inc. now owns 123,711 shares of the company’s stock valued at $356,000 after acquiring an additional 3,100 shares during the period. Finally, Farther Finance Advisors LLC lifted its stake in shares of Fulcrum Therapeutics by 108.3% during the third quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after acquiring an additional 3,697 shares during the period. Institutional investors and hedge funds own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.